版本:
中国

FDA approves Tesaro's ovarian cancer drug

March 27 The U.S. Food and Drug Administration on Monday approved Tesaro Inc's drug, niraparib, for the treatment of recurrent ovarian cancer.

Epithelial ovarian, fallopian tube or primary peritoneal cancer affects the tissue covering the ovary or lining of the fallopian tube or abdominal wall. (Reporting by Akankshita Mukhopadhyay in Bengaluru)

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐